Want to join the conversation?
Drugmaker $VRTX reported a narrower 1Q16 loss driven by product revenue from cystic fibrosis treating drugs Orkambi and Kalydeco. Net loss narrowed to $41.63MM or $0.17 per share from $198.61MM or $0.83 per share last year. Revenue grew to $398.08MM from $138.51MM. Non-GAAP EPS was $0.09 compared to loss of $0.62 per share a year ago.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.